Latest News

Crescent Diagnostics Appoints Brendan K. Farrell as CEO.

Dublin, Ireland.  4 April 2012.  Crescent Diagnostics Ltd (“Crescent”), a medical diagnostics company, which has developed a proprietary predictive test for osteoporosis, today announced the appointment of Brendan K. Farrell as Chief Executive Officer.  Brendan has o

Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug

March 22, 2012. CAMBRIDGE, UK – XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.  The drug, a selective inhibitor of

Covagen nominates bispecific TNF/IL-17A inhibitor as drug candidate to enter preclinical development

Zürich-Schlieren, Switzerland, December 12, 2011.  Covagen announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases such as rheumatoid arthritis (RA), psoriasis and